June 2010 Blog Posts (34)

Cancer Biology of Multiple Myeloma and Bortezomib (Velcade)

Multiple myeloma is a type of B-cell neoplasm characterized by the slow proliferation of well-differentiated plasma cells in the bone marrow. Although mature plasma cells are the predominant type of cell found in multiple myeloma, pre-B, myeloid, and T-cells are coexpressed with the mature plasma cell. The population of malignant cells is collectively refrerred to as myeloma cells.


Multiple myeloma tumor progression is a multistep process that can be described to occur in 3…
Continue

Added by Roxanne Engel, PhD on June 28, 2010 at 1:47pm — No Comments

Study Shows That Less Half of Breast Cancer Patients Adhere to Hormonal Therapy Regimen

A new study of nearly 8,800 women with early-stage breast cancer found that fewer than half – approximately 49% – completed their full regimen of hormone therapy… Continue

Added by Peter Hofland, PhD on June 28, 2010 at 7:00am — No Comments

Landmark Study Finds Startling 20-year Gap in Life Expectancy in Cancer Survival Between Population Groups in California

In a landmark study, scientists from the Cancer Prevention Institute of California (CPIC), the nation's premier organization dedicated to preventing cancer and to reducing its burden where it cannot yet be prevented, have discovered a startling 19.6-year gap in life expectancy between poor black men and affluent Asian women.



According to the research, Asian females with the highest socioeconomic status had a… Continue

Added by Peter Hofland, PhD on June 28, 2010 at 12:30am — No Comments

Nektar Announces Phase I Dosing of NKTR-102 in Combination with 5-FU/Leucovorin in Refractory Solid Tumor Cancers

The first patients have been dosed in a new Phase I dose-escalation clinical study to evaluate NKTR-102, Nektar Therapeutics' lead oncology compound, in combination with 5-fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers. The study is being conducted at University Hospitals Case Medical Center of the Case Comprehensive Cancer Center in Cleveland, Ohio.



NKTR-102, a novel topoisomerase I inhibitor-polymer conjugate compound, was invented by…

Continue

Added by Peter Hofland, PhD on June 24, 2010 at 5:30am — No Comments

ESMO: Significant Improvement in Progression-free Survival for Patients with Advanced Pancreatic Neuroendocrine Tumors

Groundbreaking studies will be presented at the ESMO 12th World Congress on Gastrointestinal Cancer next week in Barcelona, Spain, including exciting new data on treatment for neuroendocrine tumors. “The presentations this year are very significant for clinicians, and outline real progress in the development of agents that are effective in managing and treating gastrointestinal diseases,” says Eric Van Cutsem, MD, PhD of the University Hospital Gasthuisberg in Leuven,…

Continue

Added by Peter Hofland, PhD on June 23, 2010 at 2:30am — No Comments

Pfizer Voluntarily Withdraws Leukemia Treatment Mylotarg from U.S. Market

Earlier today, Pfizer Inc. announced that it voluntary withdraws gemtuzumab ozogamicin (Mylotarg) from the U.S.market. The drug is being used for patients with acute myeloid leukemia (AML), a bone marrow cancer. The company took the action at the request of the U.S. Food and Drug Administration after results from a recent clinical trial raised new concerns about the product’s safety and the drug failed to demonstrate clinical benefit to patients enrolled in… Continue

Added by Peter Hofland, PhD on June 21, 2010 at 2:00pm — 1 Comment

Nilotinib (Tasigna®) Demonstrates Major Treatement Advance Over Imatinib (Glivec®) For Newly Diagnosed Chronic Myeloid Leukemia Patients

Following a priority review, the US Food and Drug Administration (FDA) has approved nilotinib (Tasigna®) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. With this approval, nilotinib becomes the first new therapeutic option for newly diagnosed patients since the introduction of imatinib (Glivec®), providing a major advance for patients with this blood cancer.



The US… Continue

Added by Peter Hofland, PhD on June 18, 2010 at 4:00pm — No Comments

FDA lifts hold on Merck's Clinical Program in NSCLC

Treatment and enrollment in a clinical trial programs with BLP25 liposome vaccine (Stimuvax®, Merck Serono, Darmstadt, Germany/Geneva, Switzerland) in patients with non-small cell lung cancer (NSCLC), which includes the Phase III studies STARTa (Stimulating Targeted Antigenic Responses To NSCLC) and INSPIREb (Stimuvax trial In Asian NSCLC Patients: Stimulating Immune Response) will restart after approval by the local regulatory authorities and ethics… Continue

Added by Peter Hofland, PhD on June 17, 2010 at 7:30am — No Comments

NExUS trial: Sorafenib (Nexavar®) does Not Meet Primary Endpoint of Overall Survival in First-Line Advanced NSCLC

The final analysis of the Phase III NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating sorafenib (Nexavar® (1), Bayer Healthcare Pharmaceuticals, Inc and Onyx Pharmaceuticals, Inc.) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint…

Continue

Added by Peter Hofland, PhD on June 14, 2010 at 6:30am — No Comments

EHA 2010: Updated Results of Phase III Study Evaluating Continuous Lenalidomide (Revlimid®) Therapy in Newly Diagnosed Multiple Myeloma

Data from a second interim analysis (median follow-up of 21 months) of a phase III, randomized, double-blind study of continuous lenalidomide (Revlimid®) for the treatment of elderly patients with newly diagnosed multiple myeloma (also known as myeloma or plasma cell myeloma) show improvement in progression-free survival (PFS), the primary endpoint of the study. The data were presented during the EHA | European Haematology Association’s annual congress being held from June 10-13…

Continue

Added by Peter Hofland, PhD on June 12, 2010 at 1:00am — No Comments

EHA 2010: Maintenance Therapy with Rituximab Halves Risk of Lymphoma Recurrence

The Phase III international PRIMA trial results, presented at the 15th Congress of the European Hematology Association (EHA) taking place from June 10 to 13 at the Fira Barcelona Gran Via in Barcelona, Spain, show that two years of rituximab ‘maintenance’ therapy reduced the risk of follicular lymphoma recurrence by 50% in patients who responded to initial chemotherapy plus rituximab induction. Maintenance therapy is a longer-term treatment given after patients achieve remission,… Continue

Added by Peter Hofland, PhD on June 11, 2010 at 11:30pm — No Comments

EHA 2010: Stem Cells can Cure Deadly Form of Anemia

Research has shown that stem cells can cure Fanconi Anemia, a genetic disorder that might reduce life expectancy by twenty years. It was demonstrated that following correction of the genetic defect cells from patients with Fanconi Anemia can be reprogrammed to make healthy stem cells. These results were presented at the 15th Congress of the European Hematology Association (EHA) being held from June 10 to 13 at the Fira Barcelona Gran Via in Barcelona,… Continue

Added by Peter Hofland, PhD on June 11, 2010 at 11:30pm — No Comments

Exciting New Scientific Results Presented at the 15th Congress of EHA | European Hematology Association

The European Hematology Association today highlighted the results of a number of exicitng sientific studies. Alle sudies were presented at 15th Congress of the European Hematology Association (EHA) taking place from June 10 to 13 at the Fira Barcelona Gran Via in Barcelona, Spain.



The EHA 2010 program included sessions on clinical, laboratory, and oncological hematology, as well as hemostasis and transfusion medicine. The topics range from stem cell… Continue

Added by Peter Hofland, PhD on June 11, 2010 at 11:30am — No Comments

EHA 2010: New Developments in Treating Leukemia

Drugs which reverse epigenetic abnormalities are looking very promising in the treatment of some blood cancers and may have a role to play in solid tumors such as lung cancer. These research results are being presented at the 15th Congress of the European Hematology Association (EHA) taking place from June 10 to 13 at the Fira Barcelona Gran Via in Barcelonin, Barcelona, Spain.



In cell biology epigenetics refers to inherited changes in gene expression caused… Continue

Added by Peter Hofland, PhD on June 11, 2010 at 11:30am — No Comments

New Medicine to Reduce Thrombosis after Hip Replacement Surgery

Results from the RE-NOVATE® II clinical trial presented today at the 15th Congress of the European Hematology Association (EHA) taking place from June 10 to 13 at the Fira Barcelona Gran Via in Barcelona, Spain, have shown that the drug dabigatran etexilate 220mg taken once daily is as effective and safe as enoxaparin 40mg in preventing venous thromboembolism (VTE) (blood clots in the leg veins) after total hip replacement surgery. The results also showed that the drug dabigatran… Continue

Added by Peter Hofland, PhD on June 11, 2010 at 11:30am — No Comments

ASCO 2010: Dasatinib Is More Effective than Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

A Phase III study (the DASISION study), has found that after one year, dasatinib (Sprycel), a highly potent BCR-ABL kinase inhibitor, is superior to the standard first-line drug, imatinib (Gleevec), for bringing about cytogenetic and molecular responses in patients newly diagnosed with chronic myeloid leukemia (CML).The study results from this Phase II study, were presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held from June 4 -…

Continue

Added by Peter Hofland, PhD on June 7, 2010 at 11:30pm — No Comments

ASCO 2010: Removing Axillary Lymph Nodes Based on Metastases in the Sentinel Node Does Not Improve Survival in Early Breast Cancer

Removing additional axillary (underarm) lymph nodes – a procedure called sentinel node biopsy (SNB) - to look for more breast cancer cells in women with limited disease spread in the sentinel node does not improve survival, according to results from a Phase III study. These findings are important because many physicians routinely opt for axillary node dissection in women with metastases in the sentinel lymph node. The results of the Phase III study were reported at the 46th Annual… Continue

Added by Peter Hofland, PhD on June 6, 2010 at 1:30pm — No Comments

ASCO 2010: New Agent, Eribulin, Derived from Marine Sponge, Increases Survival Among Women with Metastatic Breast Cancer

A Phase III randomized trial finds that a new chemotherapy agent, eribulin mesylate (E7389, E), extends median overall survival by about 2.5 months among women with locally recurrent or metastatic breast cancer who had already been heavily treated with conventional therapies.



Worldwide, more than one million women a year are diagnosed with breast cancer.[1] Approximately 50 percent of women worldwide initially diagnosed with breast cancer are expected to… Continue

Added by Peter Hofland, PhD on June 6, 2010 at 1:30pm — No Comments

ASCO 2010: Progress in the Fight Against Breast Cancer

Studies describing new advances in the fight against breast cancer were released today at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held from June 4 - 8 in Chicago, Illinois



“The studies presented today provide us with new insight into the treatment and behavior of breast cancer, especially for difficult-to-treat metastatic disease,” said Eric P. Winer, MD, professor of medicine at Harvard Medical School. “We’re also… Continue

Added by Peter Hofland, PhD on June 6, 2010 at 1:00pm — No Comments

ASCO 2010: Bevacizumab Prolongs Progression-Free Survival in Women with Advanced Ovarian Cancer

A Phase III Gynecologic Oncology Group (GOG) clinical trial finds that adding bevacizumab (Avastin®), a humanized anti-VEGF monoclonal antibody, to initial chemotherapy treatment – and then giving bevacizumab as maintenance therapy – significantly slows disease progression in women with advanced epithelial ovarian, primary peritoneal or fallopian tube cancer. The results of the study were presented during the 46th annual meeting of the American Society of Clinical…

Continue

Added by Peter Hofland, PhD on June 6, 2010 at 11:30am — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+